On September 29, SBP GROUP rose 3.18% in regular trading, trading at HKD 5.675/share, with turnover of HKD 55.0016 million. The stock was buoyed by a freshly announced strategic partnership between its subsidiary and a major European pharmaceutical company.

According to a filing dated September 28, subsidiary Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with Germany-based STADA Arzneimittel for the commercialization of pembrolizumab biosimilar TQB3570 across the EU, Switzerland, the U.K., and the CIS region. Chia Tai Tianqing will receive an upfront payment and is eligible for development, regulatory, and sales milestone payments totaling up to EUR 53 million, along with a double-digit profit share. The two parties also hold options to add up to three additional biosimilar molecules in oncology and immunology.

Notably, SBP GROUP has accumulated USD 355 million in upfront and near-term milestone payments so far this year, with potential total deal value reaching USD 3.4 billion, underscoring its accelerating global licensing strategy. Management recently reiterated double-digit full-year revenue growth guidance, with innovative drug sales and licensing income expected to contribute half of total revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)